genOway Société anonyme
Market Cap
€32.3m
Last Updated
2021/06/17 20:05 UTC
Data Sources
Company Financials
Executive Summary
genOway Société anonyme, a biotechnology company, develops, manufactures, commercializes, and sells of custom genetically modified mouse, rat, and cell line models worldwide. More Details
Risk Analysis
+ 1 more risk
Snowflake Analysis
Imperfect balance sheet with weak fundamentals.
Share Price & News
How has genOway Société anonyme's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ALGEN is more volatile than 75% of French stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: ALGEN's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of French stocks.
Market Performance
7 Day Return
-1.3%
ALGEN
-1.8%
FR Biotechs
1.5%
FR Market
1 Year Return
75.8%
ALGEN
29.0%
FR Biotechs
35.4%
FR Market
Return vs Industry: ALGEN exceeded the French Biotechs industry which returned 29% over the past year.
Return vs Market: ALGEN exceeded the French Market which returned 35.4% over the past year.
Shareholder returns
| ALGEN | Industry | Market | |
|---|---|---|---|
| 7 Day | -1.3% | -1.8% | 1.5% |
| 30 Day | 5.7% | -3.2% | 4.9% |
| 90 Day | 2.5% | -7.1% | 11.0% |
| 1 Year | 75.8%75.8% | 29.0%29.0% | 39.5%35.4% |
| 3 Year | 134.0%134.0% | -13.4%-13.5% | 36.1%24.8% |
| 5 Year | 160.7%160.7% | -44.8%-44.8% | 88.9%60.7% |
Long-Term Price Volatility Vs. Market
How volatile is genOway Société anonyme's share price compared to the market and industry in the last 5 years?
Simply Wall St News
8 months ago | Simply Wall St
Is genOway (EPA:ALGEN) A Risky Investment?Valuation
Is genOway Société anonyme undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether genOway Société anonyme is trading at an attractive price based on the cash flow it is expected to produce in the future. But as genOway Société anonyme has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
Future Growth
How is genOway Société anonyme forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
26.5%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as genOway Société anonyme has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Past Performance
How has genOway Société anonyme performed over the past 5 years?
-46.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ALGEN is currently unprofitable.
Growing Profit Margin: ALGEN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ALGEN is unprofitable, and losses have increased over the past 5 years at a rate of 46.3% per year.
Accelerating Growth: Unable to compare ALGEN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALGEN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (21.8%).
Return on Equity
High ROE: ALGEN has a negative Return on Equity (-7.64%), as it is currently unprofitable.
Financial Health
How is genOway Société anonyme's financial position?
Financial Position Analysis
Short Term Liabilities: ALGEN's short term assets (€14.5M) exceed its short term liabilities (€7.9M).
Long Term Liabilities: ALGEN's short term assets (€14.5M) exceed its long term liabilities (€10.6M).
Debt to Equity History and Analysis
Debt Level: ALGEN's debt to equity ratio (119.7%) is considered high.
Reducing Debt: ALGEN's debt to equity ratio has increased from 0.3% to 119.7% over the past 5 years.
Debt Coverage: ALGEN's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if ALGEN's interest payments on its debt are well covered by EBIT.
Balance Sheet
Dividend
What is genOway Société anonyme current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ALGEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ALGEN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ALGEN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ALGEN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ALGEN's dividend in 3 years as they are not forecast to pay a notable one for the French market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.3yrs
Average board tenure
CEO
Alexandre Fraichard
2.42yrs
Tenure
Dr. Alexandre Fraichard, MBA, HEC, Co-Founded GenOway S.A. in 1999 and also serves as its General Manager since July 2020. Dr. Fraichard served as Chief operating Officer at GenOway S.A. since May 2019. He...
Board Members
Experienced Board: ALGEN's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 20.2%.
Top Shareholders
Company Information
genOway Société anonyme's company bio, employee growth, exchange listings and data sources
Key Information
- Name: genOway Société anonyme
- Ticker: ALGEN
- Exchange: ENXTPA
- Founded: 1999
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: €32.318m
- Shares outstanding: 8.32m
- Website: https://www.genoway.com
Number of Employees
Location
- genOway Société anonyme
- Technopark 2
- 31 Rue Saint Jean-de-Dieu
- Lyon
- Rhône-Alpes
- 69007
- France
Listings
Biography
genOway Société anonyme, a biotechnology company, develops, manufactures, commercializes, and sells of custom genetically modified mouse, rat, and cell line models worldwide. It produces customized mouse m...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/06/17 20:05 |
| End of Day Share Price | 2021/06/17 00:00 |
| Earnings | 2020/12/31 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.